Quasar Medical Strengthens Global CDMO Platform with Acquisition of Nordson Medical's Galway and Tecate Facilities
Quasar Medical has completed the acquisition of Nordson Corporation's (NASDAQ: NDSN) design & development contract manufacturing facilities in Galway, Ireland, and Tecate, Mexico. This strategic move transforms Quasar into a fully integrated Contract Development and Manufacturing Organization (CDMO), expanding its workforce by nearly 200 employees.
The acquisition adds two FDA-registered, ISO 13485-certified facilities in key MedTech regions. The Galway facility will serve as an innovation hub for design & development of medical devices, while the Tecate location will provide cost-effective, high-volume manufacturing capabilities. The expansion strengthens Quasar's ability to offer end-to-end solutions for complex interventional devices, from concept to commercialization.
Quasar Medical ha completato l'acquisizione degli stabilimenti di progettazione e sviluppo di Nordson Corporation (NASDAQ: NDSN) a Galway, Irlanda e a Tecate, Messico. Questa operazione strategica trasforma Quasar in un'organizzazione CDMO (Contract Development and Manufacturing Organization) completamente integrata, aumentando il proprio organico di quasi 200 dipendenti.
L'accordo include due strutture registrate dalla FDA e certificate ISO 13485 situate in regioni chiave del settore MedTech. La sede di Galway funger脿 da centro d'innovazione per la progettazione e lo sviluppo di dispositivi medici, mentre lo stabilimento di Tecate offrir脿 capacit脿 produttive ad alto volume e a costi competitivi. L'espansione rafforza la capacit脿 di Quasar di fornire soluzioni end-to-end per dispositivi interventistici complessi, dal concetto fino alla commercializzazione.
Quasar Medical ha finalizado la adquisici贸n de las instalaciones de dise帽o y desarrollo de Nordson Corporation (NASDAQ: NDSN) en Galway, Irlanda y Tecate, M茅xico. Esta decisi贸n estrat茅gica convierte a Quasar en una Organizaci贸n de Desarrollo y Fabricaci贸n por Contrato (CDMO) totalmente integrada, ampliando su plantilla en casi 200 empleados.
La adquisici贸n incorpora dos instalaciones registradas ante la FDA y certificadas ISO 13485 en regiones clave del sector MedTech. La planta de Galway funcionar谩 como un centro de innovaci贸n para el dise帽o y desarrollo de dispositivos m茅dicos, mientras que la de Tecate proporcionar谩 capacidades de fabricaci贸n de alto volumen y rentable. La expansi贸n refuerza la capacidad de Quasar para ofrecer soluciones integrales para dispositivos intervencionistas complejos, desde el concepto hasta la comercializaci贸n.
Quasar Medical鞚� Nordson Corporation(NASDAQ: NDSN)鞚� 靹り硠 氚� 臧滊皽 瓿勳暯 鞝滌“ 鞁滌劋鞚� 鞎勳澕霝滊摐 Galway鞕赌 氅曥嫓旖� Tecate鞐愳劀 鞚胳垬 鞕勲頄堨姷雼堧嫟. 鞚措矆 鞝勲灥鞝� 臁办箻搿� Quasar電� 鞕勳爠 韱淀暕順� CDMO(Contract Development and Manufacturing Organization)搿� 鞝勴櫂霅橂┌, 鞚鸽牓鞚� 瓯办潣 200氇� 电橃柎雮╇媹雼�.
鞚措矆 鞚胳垬搿� FDA 霌彪 氚� ISO 13485 鞚胳鞚� 氚涭潃 霊� 臧滌潣 鞁滌劋鞚� 頃奠嫭 MedTech 歆�鞐棎 於旉皜霅╇媹雼�. Galway 鞁滌劋鞚� 鞚橂旮瓣赴 靹り硠 氚� 臧滊皽鞚� 鞙勴暅 順侅嫚 項堧笇搿� 旮半姤頃橁碃, Tecate 鞁滌劋鞚� 牍勳毄 須湪鞝侅澑 雽�霟� 靸濎偘 電ル牓鞚� 鞝滉车頃╇媹雼�. 鞚措矆 頇曥灔鞚� 旎厜攵�韯� 靸侅毄頇旉箤歆� 氤奠灐頃� 欷戩灛鞝� 旮瓣赴毳� 鞙勴暅 鞐旊摐韴棓霌� 靻旊（靺� 鞝滉车 鞐焿鞚� 臧曧檾頃╇媹雼�.
Quasar Medical a finalis茅 l'acquisition des installations de conception et d茅veloppement de Nordson Corporation (NASDAQ: NDSN) 脿 Galway, Irlande et 脿 Tecate, Mexique. Cette op茅ration strat茅gique transforme Quasar en une CDMO (Contract Development and Manufacturing Organization) pleinement int茅gr茅e, augmentant ses effectifs d'environ 200 employ茅s.
L'acquisition ajoute deux sites enregistr茅s aupr猫s de la FDA et certifi茅s ISO 13485 dans des r茅gions cl茅s du MedTech. L'茅tablissement de Galway servira de p么le d'innovation pour la conception et le d茅veloppement de dispositifs m茅dicaux, tandis que celui de Tecate fournira des capacit茅s de production 脿 fort volume et 脿 moindre co没t. Cette expansion renforce la capacit茅 de Quasar 脿 offrir des solutions de bout en bout pour des dispositifs interventionnels complexes, du concept 脿 la commercialisation.
Quasar Medical hat die 脺bernahme der Design- und Entwicklungslieferwerke von Nordson Corporation (NASDAQ: NDSN) in Galway, Irland und Tecate, Mexiko abgeschlossen. Dieser strategische Schritt wandelt Quasar in eine voll integrierte Contract Development and Manufacturing Organization (CDMO) um und erweitert die Belegschaft um fast 200 Mitarbeiter.
Die Akquisition umfasst zwei FDA-registrierte, nach ISO 13485 zertifizierte Standorte in wichtigen MedTech-Regionen. Der Standort in Galway wird als Innovationszentrum f眉r Design und Entwicklung medizinischer Ger盲te dienen, w盲hrend der Standort in Tecate kosteneffiziente Produktionskapazit盲ten f眉r hohe St眉ckzahlen bereitstellt. Die Expansion st盲rkt Quasars F盲higkeit, End-to-End-L枚sungen f眉r komplexe interventionelle Ger盲te vom Konzept bis zur Kommerzialisierung anzubieten.
- Expansion of global presence with two FDA-registered, ISO 13485-certified facilities in strategic MedTech regions
- Addition of 200 skilled employees including expert development engineers and technicians
- Enhanced end-to-end capabilities from product development to high-volume manufacturing
- Increased cleanroom footprint and technical expertise in medical device manufacturing
- Strategic positioning in both European and North American markets improving customer proximity
- Integration challenges with merging operations and workforce from two different facilities
- Potential transition risks for existing customers and suppliers
- Increased operational complexity managing facilities across multiple regions
Insights
Nordson divests medical contract manufacturing facilities to Quasar, shifting away from this segment while strengthening Quasar's end-to-end CDMO capabilities.
Nordson Corporation (NDSN) has completed the divestiture of its design and development contract manufacturing operations in Galway, Ireland, and Tecate, Mexico to Quasar Medical. This transaction represents a strategic realignment for Nordson, allowing the company to potentially focus on its core industrial precision technology businesses while transferring its medical contract manufacturing capabilities to a specialized player.
The divested facilities are both FDA-registered and ISO 13485-certified, indicating their compliance with rigorous medical device manufacturing standards. The Galway site specializes in design and development for complex medical components including extrusions, braiding, balloons, and catheters, while the Tecate facility offers high-volume manufacturing capabilities.
From Nordson's perspective, this divestiture likely represents a portfolio optimization strategy to streamline operations. For investors, the key question centers on whether this transaction aligns with Nordson's long-term strategic direction and how the proceeds might be redeployed. The transaction transfers approximately 200 employees to Quasar, indicating a meaningful segment of Nordson's workforce.
While financial terms weren't disclosed, the deal's impact on Nordson's balance sheet and future earnings potential remains an important consideration. The divestiture reduces Nordson's exposure to the medical contract manufacturing sector while potentially allowing greater focus on its industrial precision technology applications where margins or growth prospects might be more favorable.
The transaction appears to reflect broader industry trends where companies are increasingly focusing on core competencies while divesting non-strategic assets, particularly in specialized manufacturing segments where scale and dedicated focus create competitive advantages.
This milestone enhances Quasar's global CDMO platform, broadening end-to-end capabilities聽and providing increased value for medical device OEMs and innovators.
GALWAY,
Quasar's evolution into a fully integrated Contract Development and Manufacturing Organization (CDMO) marks a transformative step, offering customers concept-to-commercialization solutions worldwide. The company is expanding its workforce by nearly 200 employees, including expert development engineers and technicians, creating new opportunities for advancement.
"This strategic acquisition marks an exciting new chapter for Quasar and the customers we serve," said Alex Wallstein, CEO of Quasar Medical. "By combining our manufacturing excellence with the world-class design, development, and assembly expertise of the Galway and
With this acquisition, Quasar strengthens its global presence with two FDA-registered, ISO 13485-certified facilities situated in key MedTech regions鈥擡urope and North America鈥攊mproving customer proximity and access. Galway,
"This is a pivotal milestone that positions Quasar as a strategic partner to our customers 鈥� not just a manufacturer," said聽Aviel Bohnik, COO of Quasar Medical. "With the addition of Galway and
A Stronger Future for Customers
By expanding its regional reach and integrating Nordson Medical's design, development, and contract manufacturing capabilities into its global platform, Quasar can now provide a seamless, end-to-end solution for complex interventional devices, including:
- Advanced product development and rapid prototyping in Galway
- Design-for-manufacturing expertise, balloon catheter and shaft development, and comprehensive testing capabilities
- Scalable manufacturing and assembly in聽Tecate, including molding, coating, packaging, and automated processes
The acquisition also greatly expands Quasar's cleanroom footprint, enhances deep technical expertise in extrusions, balloons, balloon catheters, braided shafts, and delivery systems, and creates more room for growth at both sites. Customers will benefit from regional access in
Quasar will collaborate closely with Nordson to ensure a seamless transition for employees, customers, and suppliers.
About
Quasar Medical聽is a global Contract Development and Manufacturing Organization (CDMO) delivering end-to-end solutions for interventional and minimally invasive medical devices. With 11 global facilities and over 4,300 employees across
View original content to download multimedia:
SOURCE Quasar Medical
FAQ
What facilities did Quasar Medical acquire from Nordson Corporation (NASDAQ: NDSN)?
How many employees will be added to Quasar Medical through this acquisition?
What manufacturing capabilities does the Galway facility bring to Quasar Medical?
What is the strategic importance of the Tecate, Mexico facility?
How will this acquisition benefit Quasar Medical's customers?
